XOMA Receives Orphan Drug Designation for Gevokizumab; OXiGENE Expands ZYBRESTAT Patient Program With Azanta Print E-mail
By Staff and Wire Reports   
Wednesday, 22 August 2012 18:32
Below is a look at some of the headlines for companies that made news in the healthcare sector on August 22, 2012.

XOMA Corporation (Nasdaq: XOMA)
, a leader in the discovery and development of therapeutic antibodies, announced gevokizumab, the company's IL-1 beta modulating antibody, has been granted Orphan Drug Designation by the U.S. FDA for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis.


=====


OXiGENE, Inc. (Nasdaq: OXGN)
, a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that the company has amended the Limited Distribution Agreement, established in December 2011, with Azanta Danmark A/S to include additional territories.

The territory originally included the European Union, including the Nordic countries and Switzerland, and Canada. The expanded territories now include Israel and South Korea. The Limited Distribution Agreement provides access to ZYBRESTAT® for the treatment of patients in Europe with anaplastic thyroid cancer (ATC) on a compassionate use basis via a named patient program, managed by Azanta A/S.

The Agreement provides a regulatory mechanism to allow healthcare professionals in Europe to prescribe ZYBRESTAT to individual ATC patients while it is still in development.




Also Wednesday:




Acura Pharmaceuticals, Inc. (NASDAQ: ACUR)
, a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today that the company will present at the Stifel Nicolaus Healthcare Conference at the Four Seasons Hotel in Boston on Wednesday, September 5, 2012.

Allezoe Medical Holdings, Inc. (OTCBB:ALZM)
announced today that its SureScreen Medical, Inc. subsidiary has received notice from the European Patent Office that it intends to grant the requested patent for the "see and treat" HPV virus diagnosis and treatment technology SureScreen is developing under an exclusive license, as soon as the remaining procedural steps have been completed.

Cord Blood America, Inc. (OTC Bulletin Board: CBAI)
("CBAI" or the "Company"), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that  President Joseph Vicente was interviewed by analyst Francis Gaskins about the Company's recent financial performance and its strategies for the future.

Diagnostic Imaging International Corp. (OTCQB:DIIG) (PINKSHEETS:DIIG)
is pleased to announce that on August 13, 2012, the Company entered into an agreement with the owners of an MRI clinic located in the greater Philadelphia region.

MedeFile International, Inc. (OTCQB: MDFI) (PINKSHEETS: MDFI)
, a leader in Internet-enabled Personal Health Record (iPHR) management solutions, today issued a formal update relating to key financial and operational matters expected to affect and further define the Company's business building strategies and future growth prospects.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter